OUTCOME OF ADULT PHILADELPHIA ACUTE LYMPHOBLASTIC LEUKEMIA IN THE IMATINIB ERA IN THE SOUTH OF TUNISIA
(Abstract release date: 05/19/16)
EHA Library. Ben Amor I. 06/09/16; 134522; PB1622
Dr. Imen Ben Amor
Contributions
Contributions
Abstract
Abstract: PB1622
Type: Publication Only
Background
The Philadelphia chromosome (Ph), t(9;22), is seen in about 20 to 30 % of adults diagnosed with acute lymphoblastic leukemia (ALL). It has been associated with poorer prognosis. Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogenic protein from this translocation have been incorporated into treatment regimens used to treat patients with Ph-positive ALL. In this study we analyzed the clinical, biological features and therapeutic results of patients with Ph ALL treated with chemotheray and Imatinib.
Aims
Determinate the outcome of Philadelphia acute lymphoblastic leukemia in the era of Imatinib in the South of Tunisia
Methods
From January 2007 to March 2015, 10 patients aged 21 to 55 years diagnosis with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia, in the department of clinical hematology of Hedi Chaker Hospital, and treated according to the GRAAPH protocol. Cytogenetic analysis and Bcr-Abl transcript was performed for all patients. Imatinib was associated with chemotherapy since 2007 at a dose of 600-800 mg / day. Hematopoietic stem cells transplantation (SCT) was indicated in patients aged under 45 years in complete remission and have a sibling related donor.
Results
Ten patients with de novo Ph ALL were treated with the GRAAPH protocol. The median age at the diagnosis was 44 years (21 to 55 years), 6 patients were aged under 45 years. Sex ratio (M/F) was 0,43. The median WBC was 28G/L (3,4 to 104 G/L). Nine patients had a transcript Bcr-Abl positive and one patient had only the t (9,22) without transcript Bcr-Abl. Eight patients (80%) achieved complete remission (CR). Among the 4 patients in CR and with indication to allogeneic SCT, only 3 patients were allograft. Among them, 2 patients are alive in good molecular response after a follow up of 4 and 2 years and the other patient died in post allogeneic transplant with acute graft versus host disease (GVHD). The 5 patients who were not allograft, 2 are alive in good molecular response after a follow up of 4 and 6 years and the other 3 patients died with disease progression .
Conclusion
In the pre-imatinib era, treatment outcomes of adult patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) were dismal. However, imatinib, in combination with conventional chemotherapy, has dramatically changed outcomes, producing approximately 95% complete remission, 80% in our study and 50% overall survival with or without allogeneic SCT.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Adult, BCR-ABL, Philadelphia chromosome
Type: Publication Only
Background
The Philadelphia chromosome (Ph), t(9;22), is seen in about 20 to 30 % of adults diagnosed with acute lymphoblastic leukemia (ALL). It has been associated with poorer prognosis. Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogenic protein from this translocation have been incorporated into treatment regimens used to treat patients with Ph-positive ALL. In this study we analyzed the clinical, biological features and therapeutic results of patients with Ph ALL treated with chemotheray and Imatinib.
Aims
Determinate the outcome of Philadelphia acute lymphoblastic leukemia in the era of Imatinib in the South of Tunisia
Methods
From January 2007 to March 2015, 10 patients aged 21 to 55 years diagnosis with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia, in the department of clinical hematology of Hedi Chaker Hospital, and treated according to the GRAAPH protocol. Cytogenetic analysis and Bcr-Abl transcript was performed for all patients. Imatinib was associated with chemotherapy since 2007 at a dose of 600-800 mg / day. Hematopoietic stem cells transplantation (SCT) was indicated in patients aged under 45 years in complete remission and have a sibling related donor.
Results
Ten patients with de novo Ph ALL were treated with the GRAAPH protocol. The median age at the diagnosis was 44 years (21 to 55 years), 6 patients were aged under 45 years. Sex ratio (M/F) was 0,43. The median WBC was 28G/L (3,4 to 104 G/L). Nine patients had a transcript Bcr-Abl positive and one patient had only the t (9,22) without transcript Bcr-Abl. Eight patients (80%) achieved complete remission (CR). Among the 4 patients in CR and with indication to allogeneic SCT, only 3 patients were allograft. Among them, 2 patients are alive in good molecular response after a follow up of 4 and 2 years and the other patient died in post allogeneic transplant with acute graft versus host disease (GVHD). The 5 patients who were not allograft, 2 are alive in good molecular response after a follow up of 4 and 6 years and the other 3 patients died with disease progression .
Conclusion
In the pre-imatinib era, treatment outcomes of adult patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) were dismal. However, imatinib, in combination with conventional chemotherapy, has dramatically changed outcomes, producing approximately 95% complete remission, 80% in our study and 50% overall survival with or without allogeneic SCT.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Adult, BCR-ABL, Philadelphia chromosome
Abstract: PB1622
Type: Publication Only
Background
The Philadelphia chromosome (Ph), t(9;22), is seen in about 20 to 30 % of adults diagnosed with acute lymphoblastic leukemia (ALL). It has been associated with poorer prognosis. Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogenic protein from this translocation have been incorporated into treatment regimens used to treat patients with Ph-positive ALL. In this study we analyzed the clinical, biological features and therapeutic results of patients with Ph ALL treated with chemotheray and Imatinib.
Aims
Determinate the outcome of Philadelphia acute lymphoblastic leukemia in the era of Imatinib in the South of Tunisia
Methods
From January 2007 to March 2015, 10 patients aged 21 to 55 years diagnosis with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia, in the department of clinical hematology of Hedi Chaker Hospital, and treated according to the GRAAPH protocol. Cytogenetic analysis and Bcr-Abl transcript was performed for all patients. Imatinib was associated with chemotherapy since 2007 at a dose of 600-800 mg / day. Hematopoietic stem cells transplantation (SCT) was indicated in patients aged under 45 years in complete remission and have a sibling related donor.
Results
Ten patients with de novo Ph ALL were treated with the GRAAPH protocol. The median age at the diagnosis was 44 years (21 to 55 years), 6 patients were aged under 45 years. Sex ratio (M/F) was 0,43. The median WBC was 28G/L (3,4 to 104 G/L). Nine patients had a transcript Bcr-Abl positive and one patient had only the t (9,22) without transcript Bcr-Abl. Eight patients (80%) achieved complete remission (CR). Among the 4 patients in CR and with indication to allogeneic SCT, only 3 patients were allograft. Among them, 2 patients are alive in good molecular response after a follow up of 4 and 2 years and the other patient died in post allogeneic transplant with acute graft versus host disease (GVHD). The 5 patients who were not allograft, 2 are alive in good molecular response after a follow up of 4 and 6 years and the other 3 patients died with disease progression .
Conclusion
In the pre-imatinib era, treatment outcomes of adult patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) were dismal. However, imatinib, in combination with conventional chemotherapy, has dramatically changed outcomes, producing approximately 95% complete remission, 80% in our study and 50% overall survival with or without allogeneic SCT.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Adult, BCR-ABL, Philadelphia chromosome
Type: Publication Only
Background
The Philadelphia chromosome (Ph), t(9;22), is seen in about 20 to 30 % of adults diagnosed with acute lymphoblastic leukemia (ALL). It has been associated with poorer prognosis. Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogenic protein from this translocation have been incorporated into treatment regimens used to treat patients with Ph-positive ALL. In this study we analyzed the clinical, biological features and therapeutic results of patients with Ph ALL treated with chemotheray and Imatinib.
Aims
Determinate the outcome of Philadelphia acute lymphoblastic leukemia in the era of Imatinib in the South of Tunisia
Methods
From January 2007 to March 2015, 10 patients aged 21 to 55 years diagnosis with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia, in the department of clinical hematology of Hedi Chaker Hospital, and treated according to the GRAAPH protocol. Cytogenetic analysis and Bcr-Abl transcript was performed for all patients. Imatinib was associated with chemotherapy since 2007 at a dose of 600-800 mg / day. Hematopoietic stem cells transplantation (SCT) was indicated in patients aged under 45 years in complete remission and have a sibling related donor.
Results
Ten patients with de novo Ph ALL were treated with the GRAAPH protocol. The median age at the diagnosis was 44 years (21 to 55 years), 6 patients were aged under 45 years. Sex ratio (M/F) was 0,43. The median WBC was 28G/L (3,4 to 104 G/L). Nine patients had a transcript Bcr-Abl positive and one patient had only the t (9,22) without transcript Bcr-Abl. Eight patients (80%) achieved complete remission (CR). Among the 4 patients in CR and with indication to allogeneic SCT, only 3 patients were allograft. Among them, 2 patients are alive in good molecular response after a follow up of 4 and 2 years and the other patient died in post allogeneic transplant with acute graft versus host disease (GVHD). The 5 patients who were not allograft, 2 are alive in good molecular response after a follow up of 4 and 6 years and the other 3 patients died with disease progression .
Conclusion
In the pre-imatinib era, treatment outcomes of adult patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) were dismal. However, imatinib, in combination with conventional chemotherapy, has dramatically changed outcomes, producing approximately 95% complete remission, 80% in our study and 50% overall survival with or without allogeneic SCT.
Session topic: E-poster
Keyword(s): Acute lymphoblastic leukemia, Adult, BCR-ABL, Philadelphia chromosome
{{ help_message }}
{{filter}}